keyword
MENU ▼
Read by QxMD icon Read
search

non radiographic axial spondyloarthritis

keyword
https://www.readbyqxmd.com/read/28498975/sustained-efficacy-safety-and-patient-reported-outcomes-of-certolizumab-pegol-in-axial-spondyloarthritis-4-year-outcomes-from-rapid-axspa
#1
Désirée van der Heijde, Maxime Dougados, Robert Landewé, Joachim Sieper, Walter P Maksymowych, Martin Rudwaleit, Filip Van den Bosch, Jürgen Braun, Philip J Mease, Alan J Kivitz, Jessica Walsh, Owen Davies, Lars Bauer, Bengt Hoepken, Luke Peterson, Atul Deodhar
Objective.: The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA. Methods.: RAPID-axSpA was a phase 3 randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Patients had a clinical diagnosis of axSpA, meeting Assessment of SpondyloArthritis international Society (ASAS) criteria, and had active disease...
May 12, 2017: Rheumatology
https://www.readbyqxmd.com/read/28482137/effects-of-long-term-etanercept-treatment-on-clinical-outcomes-and-objective-signs-of-inflammation-in-early-non-radiographic-axial-spondyloarthritis-104-week-results-from-the-embark-study
#2
Maxime Dougados, Désirée van der Heijde, Joachim Sieper, Jürgen Braun, Gustavo Citera, Jan Lenaerts, Filip van den Bosch, James Cheng-Chung Wei, Ron Pedersen, Randi Bonin, Heather Jones, Lisa Marshall, Isabelle Logeart, Bonnie Vlahos, Jack F Bukowski, Walter P Maksymowych
OBJECTIVE: To evaluate the long-term clinical and imaging efficacy of etanercept in patients with early, active non-radiographic axial spondyloarthritis (nr-axSpA). METHODS: Adult patients who satisfied Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA, but not modified New York radiographic criteria, with symptom duration >3 months to <5 years, and who were unresponsive to ≥2 NSAIDs, received double-blind etanercept 50 mg/week or placebo for 12 weeks, followed by open-label etanercept 50 mg/week to week 104...
May 8, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28456926/prevalence-of-hla-b27-in-the-general-population-and-in-patients-with-axial-spondyloarthritis-in-saudi-arabia
#3
Mohammed A Omair, Fatmah K AlDuraibi, Mohammed K Bedaiwi, Sultana Abdulaziz, Waleed Husain, Maha El Dessougi, Hind Alhumaidan, Hana J Al Khabbaz, Ibrahim Alahmadi, Maha A Omair, Salman Al Saleh, Khalid Alismael, Moheeb Al Awwami
The prevalence of HLA-B27 in the general population and in axial spondyloarthritis (axSpA) patients in Saudi Arabia is unknown. The aim of this study was to evaluate the prevalence of HLA-B27 in these two populations and describe the delay in diagnosis of axSpA patients. The prevalence of HLA-B27 in the general population was evaluated using cord blood and healthy organ transplant donor databases. Data from patients with axSpA were collected retrospectively from five centers. Ankylosing spondylitis (AS) was diagnosed based on a positive X-ray, as evaluated by two independent readers...
April 29, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28387855/non-radiographic-axial-spondyloarthritis-patients-without-initial-evidence-of-inflammation-may-develop-objective-inflammation-over-time
#4
Xenofon Baraliakos, Joachim Sieper, Su Chen, Aileen L Pangan, Jaclyn K Anderson
Objectives.: In patients with active axial spondyloarthritis (axSpA), inflammation in the SIJ or spine on MRI, an elevated CRP level or both are considered useful objective assessments for disease activity and initiation of TNF antagonists. The aim of this post hoc analysis of the randomized, double-blind ABILITY-1 study (NCT00939003) was to assess changes in objective inflammation over time. Methods.: Patients with non-radiographic axSpA (nr-axSpA) were randomized to receive adalimumab 40 mg every other week or placebo for 12 weeks in ABILITY-1...
April 5, 2017: Rheumatology
https://www.readbyqxmd.com/read/28376259/non-radiographic-axial-spondyloarthritis-with-sacroiliitis-detected-by-tomosynthesis
#5
Kurisu Tada, Shigeto Kobayashi, Michihiro Ogasawara, Hisashi Inoue, Ken Yamaji, Naoto Tamura
No abstract text is available yet for this article.
April 4, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28364275/magnetic-resonance-imaging-in-diffuse-idiopathic-skeletal-hyperostosis-similarities-to-axial-spondyloarthritis
#6
Uri Arad, Ori Elkayam, Iris Eshed
Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory condition that involves calcification and ossification of the spinal ligaments and entheses. While, characteristic magnetic resonance imaging (MRI) lesions of the spine in patients with axial spondyloarthritis, another enthesitis-related disease, have been described and defined, there is a paucity of information regarding the MRI findings in DISH. The aim of this study was to describe the MRI findings of patients with DISH. We collected computed tomography studies with findings characteristic of DISH and that also had corresponding and concurrent MRI studies of the spine...
March 31, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28283515/comparison-of-mri-with-radiography-for-detecting-structural-lesions-of-the-sacroiliac-joint-using-ct-as-standard-of-reference-results-from-the-simact-study
#7
Torsten Diekhoff, Kay-Geert A Hermann, Juliane Greese, Carsten Schwenke, Denis Poddubnyy, Bernd Hamm, Joachim Sieper
OBJECTIVE: Radiographs of sacroiliac (SI) joints are used for the detection of structural damage in patients with axial spondyloarthritis (axSpA), but are often difficult to interpret. Here, we address the question how the T1-weighted MRI (T1w MRI) sequence compares with radiography for SI joints' structural lesions using low-dose CT as the standard of reference. METHODS: Radiographs, T1w MRI and low-dose CT of the SI joints from 110 patients (mean age 36.1 (19-57) years, 52% males and 48% females; 53% with axSpA, 21 non-radiographic axSpA and 32% radiographic axSpA, 47% with non-SpA) referred to the rheumatologist because of unclear chronic back pain, but possible axSpA, were scored for structural lesions (erosions, sclerosis, joint space changes and an overall impression of positivity)...
March 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28240587/evaluation-of-whether-extremely-high-enthesitis-or-bath-ankylosing-spondylitis-disease-activity-index-basdai-scores-suggest-fibromyalgia-and-confound-the-anti-tnf-response-in-early-non-radiographic-axial-spondyloarthritis
#8
Maxime Dougados, Isabelle Logeart, Annette Szumski, Javier Coindreau, Heather Jones
OBJECTIVES: Differentiating between pain from spondyloarthritis (SpA) and pain from fibromyalgia is challenging. We evaluated patients with non-radiographic axial SpA (nr-axSpA) to determine the percentage of patients with extremely high enthesitis and/or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, the relationship between extreme scores and depression, and the effect of extreme scores on treatment outcomes with etanercept. METHODS: Patients with nr-axSpA received double-blind etanercept 50 mg or placebo weekly and were divided into those who did vs did not have extreme scores at baseline...
February 23, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28216193/frequency-of-concomitant-fibromyalgia-in-rheumatic-diseases-monocentric-study-of-691-patients
#9
Angelique Fan, Bruno Pereira, Anne Tournadre, Zuzana Tatar, Sandrine Malochet-Guinamand, Sylvain Mathieu, Marion Couderc, Martin Soubrier, Jean-Jacques Dubost
OBJECTIVE: Fibromyalgia (FM) is a confounding factor for diagnosing and assessing rheumatic disease activity. This study sought to assess the extent of this syndrome in rheumatism patients at a French rheumatology department. METHOD: This monocentric epidemiological study enrolled all patients consulting due to rheumatoid arthritis (RA), spondyloarthritis (SpA), or connective tissue disease (CTD). FM diagnosis was confirmed or excluded according to the rheumatologist opinion and the 1990 American College of Rheumatology (ACR) criteria...
January 18, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28197884/therapies-of-early-advanced-and-late-onset-forms-of-axial-spondyloarthritis-and-the-need-for-treat-to-target-strategies
#10
REVIEW
Nurullah Akkoc, Gercek Can, Salvatore D'Angelo, Angela Padula, Ignazio Olivieri
PURPOSE OF REVIEW: This study aims to provide an update on current status of pharmacological therapies in early and advanced stages of axial spondyloarthritis (axSpA), as well as its late onset forms, and to discuss the need for treat to target strategies in this entity. RECENT FINDINGS: Efficacy of TNF inhibitors has been assessed in randomized controlled trials in axSpA, which included patients who had non-radiographic axSpA according to the ASAS classification criteria...
February 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28176964/efficacy-and-safety-of-biological-and-targeted-synthetic-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#11
Alexandre Sepriano, Andrea Regel, Désirée van der Heijde, Jürgen Braun, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
OBJECTIVES: To update the evidence for the efficacy and safety of (b)biological and (ts)targeted-synthetic disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2016 update of the Assessment of SpondyloArthritis international Society/European League Against Rheumatism (ASAS/EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2009-2016) for randomised controlled trials (RCT), including long-term extensions, strategy trials and observational studies (the latter was only for safety assessment and a comparator was required)...
2017: RMD Open
https://www.readbyqxmd.com/read/28124744/-inflammatory-spinal-diseases-axial-spondyloarthritis-central-importance-of-imaging
#12
X Baraliakos, M Fruth, U Kiltz, J Braun
The diagnosis of axial spondyloarthritis (axSpA) includes classical ankylosing spondylitis (AS) as well as earlier stages and abortive courses of the disease, in which structural alterations have not yet occurred. These are classified as non-radiographic axSpA (nr-axSpa). Inflammatory changes in the entire axial skeleton are characteristic for axSpA and can be visualized by magnetic resonance imaging (MRI), while in most patients structural alterations, such as new bone formation with syndesmophytes and ankylosis develop in the later course of the disease...
March 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28110981/axial-spondyloarthritis
#13
REVIEW
Joachim Sieper, Denis Poddubnyy
The term axial spondyloarthritis covers both patients with non-radiographic and radiographic axial spondyloarthritis, which is also termed ankylosing spondylitis. The disease usually starts in the third decade of life with a male to female ratio of two to one for radiographic axial spondyloarthritis and of one to one for non-radiographic axial spondyloarthritis. More than 90% heritabilty has been estimated, the highest genetic association being with HLA-B27. The pathogenic role of HLA-B27 is still not clear although various hypotheses are available...
January 19, 2017: Lancet
https://www.readbyqxmd.com/read/28099816/new-treatment-options-and-emerging-drugs-for-axial-spondyloarthritis-biological-and-targeted-synthetic-agents
#14
REVIEW
Eric Toussirot
Ankylosing spondylitis (AS) and axial spondyloarthritis (ax SpA) are chronic inflammatory diseases mainly involving the axial skeleton. Pharmacological treatments for AS and ax SpA usually include local glucocorticoid injections, NSAIDs and anti-TNFα agents. Since around 30% to 40% of patients are non responders or intolerant to anti-TNFα agents, we need new therapeutic options for AS and ax SpA. Areas covered: This review describes the new biological agents that can be used or are in development for AS or ax SpA as well as emerging synthetic targeted drugs...
February 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28087505/2016-update-of-the-asas-eular-management-recommendations-for-axial-spondyloarthritis
#15
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados, Floris van Gaalen, Pál Géher, Irene van der Horst-Bruinsma, Robert D Inman, Merryn Jongkees, Uta Kiltz, Tore K Kvien, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compàn, Salih Ozgocmen, Fernando M Pimentel-Santos, John Reveille, Martin Rudwaleit, Jochen Sieper, Percival Sampaio-Barros, Dieter Wiek, Jürgen Braun
To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28064208/work-disability-in-non-radiographic-axial-spondyloarthritis-patients-before-and-after-start-of-anti-tnf-therapy-a-population-based-regional-cohort-study-from-southern-sweden
#16
Johan K Wallman, Anna Jöud, Tor Olofsson, Lennart T H Jacobsson, Henning Bliddal, Lars E Kristensen
OBJECTIVE: The aim was to assess work-loss days before and after commencement of anti-TNF treatment in patients with non-radiographic axial spondylarthritis (nr-axSpA). METHODS: Bionaïve nr-axSpA patients (n = 75), aged 17-62 years, fulfilling the Assessment of SpondyloArthritis international Society criteria for axial spondyloarthritis and starting anti-TNF treatment during 2004-11, were retrieved from the observational South Swedish Arthritis Treatment Group study...
January 7, 2017: Rheumatology
https://www.readbyqxmd.com/read/28035438/should-axial-spondyloarthritis-without-radiographic-changes-be-treated-with-anti-tnf-agents
#17
REVIEW
Andrew Keat, Alexander N Bennett, Karl Gaffney, Helena Marzo-Ortega, Raj Sengupta, Tamara Everiss
A spectrum of disease extends beyond the rigid confines of ankylosing spondylitis (AS). Axial spondyloarthritis (axSpA) encompasses non-radiographic axSpA (nr-axSpA) in individuals without established radiographic changes but with other clinical/imaging axSpA features and AS in those with definite sacroiliac joint changes on pelvic X-rays. A broad consensus about the management of nr-axSpA is emerging among clinicians, but the evidence base remains open to question. To explore whether nr-axSpA and AS should be treated similarly, we examined the literature on their prevalence, natural history, disease burden, and treatment...
March 2017: Rheumatology International
https://www.readbyqxmd.com/read/27997346/efficiency-of-treatment-with-non-steroidal-anti-inflammatory-drugs-according-to-current-recommendations-in-patients-with-radiographic-and-non-radiographic-axial-spondyloarthritis
#18
Xenofon Baraliakos, Uta Kiltz, Soeren Peters, Heiner Appel, Friedrich Dybowski, Manfred Igelmann, Ludwig Kalthoff, Dietmar Krause, Hans-Juergen Menne, Ertan Saracbasi-Zender, Elmar Schmitz-Bortz, Mathura Vigneswaran, Juergen Braun
OBJECTIVE: NSAIDs are first-line therapy in axial SpA (axSpA). The proportion of patients responding to NSAIDs and differences between AS and non-radiographic axSpA (nr-axSpA) in this regard have not been studied in detail to date. The aim of this study was to examine the proportion of patients with AS and nr-axSpA responding to NSAIDs according to current treatment recommendations. METHODS: Consecutive anti-TNF-naïve patients with nr-axSpA and AS (n = 50 each) were included if their BASDAI score was ⩾4 without having received maximal NSAID doses...
January 2017: Rheumatology
https://www.readbyqxmd.com/read/27991410/reply-to-the-editorial-can-we-currently-and-confidently-assess-the-true-burden-of-illness-due-to-non-radiographic-axial-spondyloarthritis-by-s-van-der-linden-and-m-a-khan
#19
Joachim Sieper, Robert Wood, Sumesh Kachroo
****************************************************************************.
November 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27991409/can-we-currently-and-confidently-assess-the-true-burden-of-illness-due-to-non-radiographic-axial-spondyloarthritis
#20
EDITORIAL
Sjef van der Linden, Muhammad A Khan
****************************************************************************.
November 2016: Clinical and Experimental Rheumatology
keyword
keyword
111757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"